Promoted Content Promoted Content

X

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
News Type filter
    Company filter
      Product Type filter
        Deal Size filter
          Upfront Payment filter
            refresh

            Product Type Full Screen

            Companies Full Screen

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Idursulfase beta

            Therapeutic Area: Genetic Disease Product Name: Hunterase

            Highest Development Status: Approved Product Type: Large molecule

            Partner/Sponsor/Collaborator: 3W Fund Management

            Deal Size: $43.0 million Upfront Cash: Undisclosed

            Deal Type: Series E Financing December 01, 2020

            Details:

            The proceeds will be used to expand the CANbridge rare disease pipeline through internal development and external partnerships, accelerate the clinical development of pre-clinical stage assets, prepare the commercial launch of Hunterase® and supplement working capital.